Drs Moriarity and Webber discuss a study evaluating neoantigen-reactive CISH knockout TIL therapy in patients with metastatic gastrointestinal cancers.
Back
Evaluating Neoantigen-Reactive CISH-Knockout TILs in Metastatic Colorectal Cancer
Emil Lou, MD, PhD, FACP, Branden Moriarity, PhD, and Beau Webber, PhD, on the applicability of CISH knockout to bolster TIL responses in GI tumors.
Evaluating Neoantigen-Reactive CISH-Knockout TILs in Metastatic Colorectal Cancer
Episodes
All
All
Emil Lou, MD, PhD, FACP, discusses the potential applicability of CRISPR-Cas9–mediated CISH knockout to bolster TIL responses in drug-refractory GI tumors.
CRISPR-Cas9–mediated CISH gene knockout TIL therapy was well tolerated and demonstrated early signals of efficacy in metastatic GI epithelial cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
FDA Grants Fast Track Designation to Varsetatug Masetecan for Relapsed/Refractory Metastatic Colorectal Cancer
5